X0609 4 2026-08-27 0001689375 Entrada Therapeutics, Inc. TRDA 0001609492 MPM BioVentures 2014, L.P. false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 false false true false 0001134657 EVNIN LUKE false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 0 0 1 0 0001134655 GADICKE ANSBERT false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 0 0 1 0 0001473930 Foley Todd false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 0 0 1 0 0001609493 MPM BioVentures 2014 (B), L.P. false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 0 0 1 0 0001609495 MPM Asset Management Investors BV2014 LLC false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 0 0 1 0 0001765021 MPM BioVentures 2014 LLC false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 0 0 1 0 0001765091 MPM BioVentures 2014 GP LLC false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 0 0 1 0 0001729504 MPM BIOVENTURES 2018 (B), L.P. false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 0 0 1 0 0001734817 MPM ASSET MANAGEMENT INVESTORS BV2018 LLC false C/O MPM BIOIMPACT 399 BOYLSTON STREET, SUITE 1100 BOSTON MA 02116 0 0 1 0 0 Common Stock 2026-08-27 4 S 0 38922 7.20 D 4279426 I See Footnote Common Stock 2026-08-28 4 S 0 3733 7.01 D 4275693 I See Footnote Common Stock 2026-08-31 4 S 0 44259 6.99 D 4231434 I See Footnote The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 18,139 by MPM BioVentures 2018, L.P. ("BV 2018"), 964 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 358 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018. The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018. See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing. /s/ Luke Evnin 2026-08-31 /s/ Ansbert Gadicke 2026-08-31 /s/ Todd Foley 2026-08-31 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P. 2026-08-31 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC 2026-08-31 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC 2026-08-31 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P. 2026-08-31 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC 2026-08-31 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P. 2026-08-31 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC 2026-08-31